D-Wave Quantum falls nearly 3% as earnings miss overshadows revenue beat
REDWOOD CITY, Calif. - Coherus BioSciences, Inc. (NASDAQ: CHRS), a commercial-stage biopharmaceutical company with a market capitalization of $93.53 million, has announced its plan to repurchase approximately $170 million of its outstanding 1.500% Convertible Senior Subordinated Notes due 2026. According to InvestingPro data, the company currently maintains a FAIR financial health score, though it operates with a significant debt burden. This transaction is conditioned upon the completion of the sale of its UDENYCA (pegfilgrastim-cbqv) franchise to Intas Pharmaceuticals Ltd., expected early in the second quarter of 2025.
The repurchase agreement involves Coherus buying back the notes at their principal amount, along with accrued and unpaid interest, from certain note holders. Following this transaction, about $60 million of the convertible notes will remain outstanding, which would significantly reduce the company’s total debt burden of $298.65 million. Coherus intends to offer a repurchase of the remaining notes at the same terms, contingent on the divestiture’s closure.
In addition, the majority holders of the convertible notes have consented to amendments to the indenture governing the notes, allowing the UDENYCA transaction. These amendments will be formalized through a supplemental indenture between Coherus and U.S. Bank Trust Company, National Association, as trustee.
Coherus BioSciences focuses on oncology, with an approved PD-1 inhibitor, LOQTORZI® (toripalimab-tpzi), and a pipeline including candidates targeting various cancers. The company’s strategy is to grow LOQTORZI sales and advance new indications for toripalimab in combination with other therapies.
The divestiture of the UDENYCA franchise is part of Coherus’s strategic shift to enhance its oncology portfolio. The proceeds from the sale are anticipated to contribute to the repurchase of the remaining convertible notes and further investment in the company’s product pipeline. With the stock down 41.52% year-to-date, InvestingPro analysis reveals 8 additional key investment factors and detailed financial metrics available to subscribers. Get access to the comprehensive Pro Research Report, part of InvestingPro’s coverage of over 1,400 US stocks, for deeper insights into Coherus’s financial health and growth potential.
The information in this article is based on a press release statement from Coherus BioSciences, Inc.
In other recent news, Coherus BioSciences reported its fourth-quarter 2024 earnings, showing a revenue of $54.1 million, which exceeded the forecasted $44.15 million. The earnings per share (EPS) were slightly better than expected, at -$0.28 compared to the anticipated -$0.30. Additionally, Coherus BioSciences announced that its shareholders have approved the sale of the UDENYCA® franchise to Intas Pharmaceuticals Ltd., marking a significant step in the company’s strategic shift. The transaction is expected to bring Coherus $250 million in cash, strengthening its financial position.
Coherus BioSciences also received an upgrade from H.C. Wainwright, with analysts maintaining a Buy rating and a $7.00 price target, influenced by the strong sales growth of its cancer treatment, Loqtorzi. In the fourth quarter, Loqtorzi sales reached $7.5 million, reflecting a 29% increase quarter over quarter. The company has been actively working on increasing awareness of the National Comprehensive Cancer Network’s guidelines, which recommend Loqtorzi as a preferred regimen for treating advanced nasopharyngeal carcinoma.
Furthermore, Coherus BioSciences is undergoing strategic transitions, including workforce reductions and focusing more on its oncology pipeline, as evidenced by its divestitures and ongoing clinical trials. The company aims to expand Loqtorzi’s market presence and anticipates that the full impact of the updated guidelines on Loqtorzi’s uptake will be seen in the latter half of 2025. These developments highlight Coherus’s efforts to strengthen its position in the oncology sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.